Jay Olson
Stock Analyst at Oppenheimer
(3.49)
# 766
Out of 4,814 analysts
238
Total ratings
38.83%
Success rate
5.6%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Upgrades: Outperform | $6 | $0.64 | +837.50% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $12.72 | +230.19% | 4 | Mar 3, 2025 | |
| PRTA Prothena Corporation | Maintains: Outperform | $58 → $62 | $9.23 | +571.72% | 13 | Feb 7, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $36.06 | -8.49% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $7.27 | +450.59% | 9 | Jan 13, 2025 | |
| QTTB Q32 Bio | Maintains: Outperform | $80 → $20 | $2.02 | +892.56% | 2 | Dec 11, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $30 | $2.21 | +1,257.47% | 1 | Dec 6, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $17 → $20 | $2.40 | +733.33% | 2 | Dec 4, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $1.74 | +762.07% | 2 | Nov 18, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 → $255 | $118.61 | +114.99% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $7.44 | +7.60% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $58.22 | +40.85% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $60 | $36.75 | +63.27% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $301.73 | +16.00% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $2.43 | +311.52% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $23.83 | +479.10% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.79 | +346.93% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $7.35 | +553.06% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $277.29 | +37.04% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $100.10 | +118.78% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.29 | +833.85% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.16 | +470.52% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.53 | +1,792.86% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $37.76 | +151.59% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $14.71 | +29.16% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.44 | +1,642.16% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $28.32 | +164.83% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.37 | +2,359.69% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $3.97 | +1,915.11% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $1.25 | +1,900.00% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $6.07 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $0.79 | +6,203.58% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $5.13 | +309.36% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.29 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.09 | +391.52% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.00 | - | 3 | Jul 11, 2017 |
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $6
Current: $0.64
Upside: +837.50%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $12.72
Upside: +230.19%
Prothena Corporation
Feb 7, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $9.23
Upside: +571.72%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $36.06
Upside: -8.49%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $7.27
Upside: +450.59%
Q32 Bio
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $2.02
Upside: +892.56%
Sagimet Biosciences
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $2.21
Upside: +1,257.47%
Terns Pharmaceuticals
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $2.40
Upside: +733.33%
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $1.74
Upside: +762.07%
Biogen
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $118.61
Upside: +114.99%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $7.44
Upside: +7.60%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $58.22
Upside: +40.85%
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $36.75
Upside: +63.27%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $301.73
Upside: +16.00%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $2.43
Upside: +311.52%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $23.83
Upside: +479.10%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.79
Upside: +346.93%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $7.35
Upside: +553.06%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $277.29
Upside: +37.04%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $100.10
Upside: +118.78%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.29
Upside: +833.85%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.16
Upside: +470.52%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.53
Upside: +1,792.86%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $37.76
Upside: +151.59%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $14.71
Upside: +29.16%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.44
Upside: +1,642.16%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $28.32
Upside: +164.83%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.37
Upside: +2,359.69%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $3.97
Upside: +1,915.11%
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.25
Upside: +1,900.00%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $6.07
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $0.79
Upside: +6,203.58%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $5.13
Upside: +309.36%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.29
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.09
Upside: +391.52%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.00
Upside: -